Related Experiment Video

Updated: May 8, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Herbal therapeutics that block the oncogenic kinase PAK1: a practical approach towards PAK1-dependent diseases and

Hiroshi Maruta1

  • 1NF/TSC Cure Org., Melbourne, Australia.

Phytotherapy Research : PTR
|August 15, 2013
PubMed

Insights

RAC/CDC42(p21)-activated kinases (PAKs), especially PAK1, are implicated in numerous diseases. Herbal therapeutics like propolis and curcumin can block PAK1 without harming healthy cells, offering a promising treatment avenue.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Disease Pathology

Background:

  • Over 35 years of research highlights the role of PAKs, particularly PAK1, in various diseases including cancer, Alzheimer's, and diabetes.
  • Currently, no FDA-approved PAK1 inhibitors are available, leaving patients reliant on alternative treatments.

Purpose of the Study:

  • To outline the pathological phenotypes associated with hyperactive PAK1.
  • To identify herbal therapeutics that effectively block PAK1 activity.
  • To assess the safety profile of these herbal PAK1 blockers.

Main Methods:

  • Review of existing literature on PAK1 function and its role in disease pathogenesis.
  • Identification and compilation of herbal compounds reported to inhibit PAK1.
  • Analysis of studies investigating the effects of herbal therapeutics on lifespan in model organisms (C. elegans, Drosophila).

Main Results:

  • Hyperactivation of PAK1 is linked to diverse pathological conditions, including solid tumors, neurodegenerative diseases, and inflammatory disorders.
  • Herbal therapeutics such as propolis and curcumin have demonstrated the ability to inhibit PAK1.
  • These natural compounds extend lifespan in model organisms and do not adversely affect normal cell growth or healthy individuals.

Conclusions:

  • Hyperactive PAK1 is a significant factor in numerous diseases, creating an unmet need for effective treatments.
  • Herbal therapeutics offer a safe and potentially effective strategy for managing PAK1-dependent diseases by inhibiting PAK1 without harmful side effects.
  • Further research into these natural compounds could lead to novel therapeutic interventions.
Keywords:
AIDSAlzheimer's diseaseKing of BittersPAK1Thunder god vinecancercurcumindiabeteslongevityneurofibromatosispropolistuberous sclerosis

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...